|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C12N 15/113 | (2010.01) |
| A61K 31/713 | (2006.01) |
| (11) | Number of the document | 3529360 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17800976.7 |
| Date of filing the European patent application | 2017-10-18 | |
| (97) | Date of publication of the European application | 2019-08-28 |
| (45) | Date of publication and mention of the grant of the patent | 2024-04-17 |
| (46) | Date of publication of the claims translation | 2024-07-25 |
| (86) | Number | PCT/US2017/057218 |
| Date | 2017-10-18 |
| (87) | Number | WO 2018/075658 |
| Date | 2018-04-26 |
| (30) | Number | Date | Country code |
| 201662409816 P | 2016-10-18 | US | |
| 201662422028 P | 2016-11-14 | US | |
| 201762472525 P | 2017-03-16 | US | |
| 201762550426 P | 2017-08-25 | US |
| (72) |
WIJNGAARD, Peter , US
KALLEND, David , US
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Metodai, skirti širdies ir kraujagyslių ligų prevencijai mažinant proproteinų konvertazės subtilizino keksino 9 (PCSK9) baltymo kiekį |
| METHODS FOR PREVENTING CARDIOVASCULAR EVENTS THROUGH PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) PROTEIN REDUCTION |
| Payment date | Validity (years) | Amount | |
| 2025-09-19 | 9 | 208.00 EUR |
| 2026-10-18 |